TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as GlobeNewsWire • 10/24/19
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in BloodGlobeNewsWire • 09/30/19
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)GlobeNewsWire • 09/23/19
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)GlobeNewsWire • 09/12/19
TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS GlobeNewsWire • 08/29/19
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/10/19
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?Zacks Investment Research • 04/01/19